Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Review Article Volume 5 Issue 6

Clinical Implications in Understanding Prostate Cancer Biology: From Androgen Receptor to Molecular Target Therapy in Metastatic Castration Resistant Prostate Cancer

Eliza Dalsasso Ricardo*, Angel AT Uchiyama, Denis S Shimba and Ariel G Kann

Department of Clinical Oncology, Hospital Alemao Oswaldo Cruz, Brazil

*Corresponding Author: Eliza Dalsasso Ricardo, Department of Clinical Oncology, Hospital Alemao Oswaldo Cruz, Brazil.

Received: April 07, 2021; Published: May 15, 2021

Abstract

Prostate cancer is one of the most common malignancies in the world. For a long time, the cornerstone of treatment for advanced disease has been the manipulation of hormonal pathway of testosterone since is well stablished that androgen receptor regulates prostate growth, differentiation and apoptosis in regular and cancer cells. However, during the treatment of metastatic disease with androgen deprivation therapy resistance mechanisms appear, which led to the development of new treatments, such as second-generation anti-androgens-like (such as enzalutamide, apalutamide and darolutamide), and abiraterone acetate. In addition to the development of this new antiandrogens the deeper knowledge about DNA damage repair and their pathways such as direct reversal, mismatch repair, base excision repair, homologous recombination and the non-homologous end joining, resulted in new opportunities of treatment. Recently, PARP inhibitors have showed their efficacy in the treatment of advanced prostate cancer. Therefore, the aim of this article is to review the current knowledge about cancer prostate biology and its clinical implications.

Keywords: Prostate Cancer; Biology; Androgen-receptor; Molecular Therapy; DNA Damage Repair; PARP Inhibitor

References

  1. Sung Hyuna., et al. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA: A Cancer Journal for Clinicians, fevereiro de (2021): 21660.
  2. "Cancer Of The Prostate - Cancer Stat Facts". SEER (2021).
  3. Grönberg Henrik. "Prostate Cancer Epidemiology". The Lancet9360 (2003): 859-864. 
  4. Mateo Joaquin., et al. "DNA Repair In Prostate Cancer: Biology And Clinical Implications". European Urology3 (2017): 417-425.
  5. Huggins C and C V Hodges. "Studies On Prostatic Cancer: I. The Effect Of Castration, Of Estrogen And Of Androgen Injection On Serum Phosphatases In Metastatic Carcinoma Of The Prostate". CA: A Cancer Journal for Clinicians4 (1972): 232-240.
  6. Tannock Ian F., et al. "Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone For Advanced Prostate Cancer". New England Journal of Medicine15 (2004): 1502-1512.
  7. de Bono Johann S., et al. "Abiraterone And Increased Survival In Metastatic Prostate Cancer". New England Journal of Medicine21 (2011): 1995-2005.
  8. Scher Howard I., et al. "Increased Survival With Enzalutamide In Prostate Cancer After Chemotherapy". New England Journal of Medicine13 (2012): 1187-1197.
  9. Chi Kim N., et al. "Apalutamide For Metastatic, Castration-Sensitive Prostate Cancer". New England Journal of Medicine1 (2019): 13-24.
  10. Fizazi Karim., et al. "Nonmetastatic, Castration-Resistant Prostate Cancer And Survival With Darolutamide". New England Journal of Medicine11 (2020): 1040-1049.
  11. Oefelein Michael G., et al. "Reassessment Of The Definition Of Castrate Levels Of Testosterone: Implications For Clinical Decision Making". Urology6 (2000): 1021-1024.
  12. SIITERI PENTTI K and JEAN D WILSON. "Testosterone Formation And Metabolism During Male Sexual Differentiation In The Human Embryo". The Journal of Clinical Endocrinology and Metabolism1 (1974): 113-125.
  13. Cunha Gerald R., et al. "Role Of Stromal-Epithelial Interactions In Hormonal Responses". Archives of Histology and Cytology5 (2004): 417-434.
  14. Deslypere JP., et al. "Testosterone And 5Α-Dihydrotestosterone Interact Differently With The Androgen Receptor To Enhance Transcription Of The MMTV-CAT Reporter Gene". Molecular and Cellular Endocrinology1-3 (1992): 15-22.
  15. Mostaghel Elahe A., et al. "Intraprostatic Androgens And Androgen-Regulated Gene Expression Persist After Testosterone Suppression: Therapeutic Implications For Castration-Resistant Prostate Cancer". Cancer Research10 (2007): 5033-5041.
  16. Limonta Patrizia., et al. "Gnrh In The Human Female Reproductive Axis". Vitamins and Hormones (2018): 27-66.
  17. Munro Neville A and MJ O'hare. "Histopathology Of The Human Adrenal Cortex". Clinics in Endocrinology and Metabolism4 (1985): 791-820.
  18. Miller Walter L. "MECHANISMS IN ENDOCRINOLOGY: Rare Defects In Adrenal Steroidogenesis". European Journal of Endocrinology3 (2018): R125-R141.
  19. Parker Keith L and Bernard P Schimmer. "Transcriptional Regulation Of The Genes Encoding The Cytochrome P-450 Steroid Hydroxylases". Vitamins and Hormones (1995): 339-370.
  20. Sanderson J Thomas. "The Steroid Hormone Biosynthesis Pathway As A Target For Endocrine-Disrupting Chemicals". Toxicological Sciences1 (2006): 3-21.
  21. Sandow Jürgen., et al. "Pituitary Gonadotropin Inhibition By A Highly Active Analog Of Luteinizing Hormone-Releasing Hormone". Fertility and Sterility2 (1978): 205-209.
  22. Gründker Carsten and Günter Emons. "The Role Of Gonadotropin-Releasing Hormone In Cancer Cell Proliferation And Metastasis". Frontiers in Endocrinology 8 (2017).
  23. Thompson Ian M. "Flare Associated With LHRH-Agonist Therapy". Reviews in Urology3 (2001): S10-14.
  24. Klotz Laurence., et al. "The Efficacy And Safety Of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study In Patients With Prostate Cancer". BJU International11 (2008): 1531-1538.
  25. Shore Neal D., et al. "Oral Relugolix For Androgen-Deprivation Therapy In Advanced Prostate Cancer". New England Journal of Medicine23 (2020): 2187-2196.
  26. Crona DJ., et al. "Androgen Receptor Targeting Drugs In Castration-Resistant Prostate Cancer And Mechanisms Of Resistance". Clinical Pharmacology and Therapeutics6 (2015): 582-589.
  27. Heidenreich Axel., et al. "EAU Guidelines On Prostate Cancer. Part II: Treatment Of Advanced, Relapsing, And Castration-Resistant Prostate Cancer". European Urology2 (2014): 467-479.
  28. Knudsen Karen E and William Kevin Kelly. "Outsmarting Androgen Receptor: Creative Approaches For Targeting Aberrant Androgen Signaling In Advanced Prostate Cancer". Expert Review of Endocrinology and Metabolism3 (2011): 483-493.
  29. Clarke Noel., et al. "Olaparib Combined With Abiraterone In Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial". The Lancet Oncology7 (2018): 975-986.
  30. Teply Benjamin A and Emmanuel S Antonarakis. "Treatment Strategies For DNA Repair-Deficient Prostate Cancer". Expert Review Of Clinical Pharmacology8 (2017): 889-898.
  31. Asim Mohammad., et al. "Synthetic Lethality Between Androgen Receptor Signalling And The PARP Pathway In Prostate Cancer". Nature Communications1 (2017).
  32. Hakem Razqallah. "DNA-Damage Repair; The Good, The Bad, And The Ugly". The EMBO Journal4 (2008): 589-605.
  33. Branzei, Dana, and Marco Foiani. "Regulation Of DNA Repair Throughout The Cell Cycle". Nature Reviews Molecular Cell Biology4 (2008): 297-308.
  34. Chatterjee Nimrat and Graham C Walker. "Mechanisms Of DNA Damage, Repair, And Mutagenesis". Environmental And Molecular Mutagenesis5 (2017): 235-263.
  35. Lang Shona., et al. "A Systematic Review Of The Prevalence Of DNA Damage Response Gene Mutations In Prostate Cancer". International Journal of Oncology (2019).
  36. Pritchard Colin C., et al. "Inherited DNA-Repair Gene Mutations In Men With Metastatic Prostate Cancer". New England Journal of Medicine5 (2016): 443-453. 
  37. Hanahan Douglas and Robert A Weinberg. "Hallmarks Of Cancer: The Next Generation". Cell5 (2011): 646-674.
  38. Burdak-Rothkamm Susanne., et al. "DNA Damage Repair Deficiency In Prostate Cancer". Trends in Cancer11 (2020): 974-984.
  39. Dall’Era Marc A., et al. "Germline And Somatic DNA Repair Gene Alterations In Prostate Cancer". Cancer13 (2020): 2980-2985.
  40. Nguyen Luan., et al. "Pan-Cancer Landscape Of Homologous Recombination Deficiency". Nature Communications1 (2020).
  41. Fridlich Ram., et al. "BRCA1 And BRCA2 Protect Against Oxidative DNA Damage Converted Into Double-Strand Breaks During DNA Replication". DNA Repair 30 (2015): 11-20.
  42. Bishop Alexander JR and Robert H Schiestl. "Homologous Recombination And Its Role In Carcinogenesis". Journal Of Biomedicine And Biotechnology2 (2002): 75-85.
  43. Wei, Yu., et al. "Germline DNA Repair Gene Mutation Landscape In Chinese Prostate Cancer Patients". European Urology3 (2019): 280-283.
  44. Fradet-Turcotte, Amélie., et al. "BRCA2 Functions: From DNA Repair To Replication Fork Stabilization". Endocrine-Related Cancer10 (2016): T1-T17.
  45. Marshall Catherine Handy., et al. "Prevalence Of DNA Repair Gene Mutations In Localized Prostate Cancer According To Clinical And Pathologic Features: Association Of Gleason Score And Tumor Stage". Prostate Cancer and Prostatic Diseases1 (2018): 59-65.
  46. Carver Brett S., et al. "Reciprocal Feedback Regulation Of PI3K And Androgen Receptor Signaling In PTEN-Deficient Prostate Cancer". Cancer Cell5 (2011): 575-586.
  47. Jamaspishvili Tamara., et al. "Clinical Implications Of PTEN Loss In Prostate Cancer". Nature Reviews Urology4 (2018): 222-234.
  48. Pei Huadong., et al. "FKBP51 Affects Cancer Cell Response To Chemotherapy By Negatively Regulating Akt". Cancer Cell3 (2009): 259-266.
  49. Gao Tianyan., et al. "PHLPP: A Phosphatase That Directly Dephosphorylates Akt, Promotes Apoptosis, And Suppresses Tumor Growth". Molecular Cell1 (2005): 13-24.
  50. Lozano Rebeca., et al. "Genetic Aberrations In DNA Repair Pathways: A Cornerstone Of Precision Oncology In Prostate Cancer". British Journal of Cancer3 (2020): 552-563.
  51. Mateo Joaquin., et al. "DNA-Repair Defects And Olaparib In Metastatic Prostate Cancer". New England Journal of Medicine18 (2015): 1697-1708.
  52. Mateo Joaquin., et al. "Olaparib In Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-Label, Randomised, Phase 2 Trial". The Lancet Oncology1 (2020): 162-174.
  53. Hussain Maha., et al. "Survival With Olaparib In Metastatic Castration-Resistant Prostate Cancer". New England Journal of Medicine24 (2020): 2345-2357.
  54. Abida W., et al. "Preliminary Results From The TRITON2 Study Of Rucaparib In Patients (Pts) With DNA Damage Repair (DDR)-Deficient Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Updated Analyses". Annals of Oncology 30 (2019): 327-v328.
  55. Abida Wassim., et al. "Non-BRCA DNA Damage Repair Gene Alterations And Response To The PARP Inhibitor Rucaparib In Metastatic Castration-Resistant Prostate Cancer: Analysis From The Phase II TRITON2 Study". Clinical Cancer Research11 (2020): 2487-2496.
  56. Smith Matthew Raymond., et al. "Phase II Study Of Niraparib In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) And Biallelic DNA-Repair Gene Defects (DRD): Preliminary Results Of GALAHAD.". Journal of Clinical Oncology7 (2019): 202-202.
  57. De Bono Johann S., et al. "TALAPRO-1: A Phase II Study Of Talazoparib (TALA) In Men With DNA Damage Repair Mutations (Ddrmut) And Metastatic Castration-Resistant Prostate Cancer (Mcrpc)—First Interim Analysis (IA).". Journal of Clinical Oncology6_suppl (2020): 119-119.
  58. "A Study Of Niraparib In Combination With Abiraterone Acetate And Prednisone Versus Abiraterone Acetate And Prednisone For Treatment Of Participants With Metastatic Prostate Cancer - Full Text View - Clinicaltrials.Gov". Gov (2021).
  59. "Talazoparib + Enzalutamide Vs. Enzalutamide Monotherapy In Mcrpc - Full Text View - Clinicaltrials.Gov". Gov (2021).
  60. Ferraldeschi, et al. "PTEN Protein Loss And Clinical Outcome From Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate". European Urology 67.4 (2015): 795-802.
  61. Lin Jie., et al. "Targeting Activated Akt With GDC-0068, A Novel Selective Akt Inhibitor That Is Efficacious In Multiple Tumor Models". Clinical Cancer Research7 (2013): 1760-1772.
  62. de Bono JS., et al. "LBA4 Ipatential150: Phase III Study Of Ipatasertib (Ipat) Plus Abiraterone (Abi) Vs Placebo (Pbo) Plus Abi In Metastatic Castration-Resistant Prostate Cancer (Mcrpc)". Annals of Oncology 31 (2020): S1153-S1154.
  63. De Bono Johann S., et al. "PI3K/AKT Pathway Biomarkers Analysis From The Phase III Ipatential150 Trial Of Ipatasertib Plus Abiraterone In Metastatic Castration-Resistant Prostate Cancer". Journal of Clinical Oncology6 (2021): 13-13.
  64. "Home - Clinicaltrials.Gov". Clinicaltrials.Gov (2021).

Citation

Citation: Eliza Dalsasso Ricardo., et al. “Clinical Implications in Understanding Prostate Cancer Biology: From Androgen Receptor to Molecular Target Therapy in Metastatic Castration Resistant Prostate Cancer”. Acta Scientific Cancer Biology 5.6 (2021): 09-19.

Copyright

Copyright: © 2021 Eliza Dalsasso Ricardo., et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US